Free Trial
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DexCom, Inc. stock logo
DXCM
DexCom
$83.45
-1.1%		$87.52
$54.11
▼
$92.59
$31.39B1.485.01 million shs1.36 million shs
Illumina, Inc. stock logo
ILMN
Illumina
$276.18
+4.4%		$225.72
$88.00
▼
$309.35
$41.69B1.412.17 million shs1.07 million shs
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$426.50
+2.7%		$384.95
$328.57
▼
$603.88
$150.63B1.462.42 million shs1.01 million shs
Insulet Corporation stock logo
PODD
Insulet
$134.08
-0.3%		$142.33
$126.40
▼
$354.88
$9.28B1.111.39 million shs426,330 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DexCom, Inc. stock logo
DXCM
DexCom
+0.13%-2.11%-0.14%+12.61%+24.54%
Illumina, Inc. stock logo
ILMN
Illumina
-1.19%-0.43%+25.35%+39.10%+170.58%
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
+0.21%+3.53%+18.63%+2.12%-7.29%
Insulet Corporation stock logo
PODD
Insulet
+0.08%+2.81%-5.49%-16.62%-57.38%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DexCom, Inc. stock logo
DXCM
DexCom
$83.45
-1.1%		$87.52
$54.11
▼
$92.59
$31.39B1.485.01 million shs1.36 million shs
Illumina, Inc. stock logo
ILMN
Illumina
$276.18
+4.4%		$225.72
$88.00
▼
$309.35
$41.69B1.412.17 million shs1.07 million shs
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$426.50
+2.7%		$384.95
$328.57
▼
$603.88
$150.63B1.462.42 million shs1.01 million shs
Insulet Corporation stock logo
PODD
Insulet
$134.08
-0.3%		$142.33
$126.40
▼
$354.88
$9.28B1.111.39 million shs426,330 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DexCom, Inc. stock logo
DXCM
DexCom
+0.13%-2.11%-0.14%+12.61%+24.54%
Illumina, Inc. stock logo
ILMN
Illumina
-1.19%-0.43%+25.35%+39.10%+170.58%
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
+0.21%+3.53%+18.63%+2.12%-7.29%
Insulet Corporation stock logo
PODD
Insulet
+0.08%+2.81%-5.49%-16.62%-57.38%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
DexCom, Inc. stock logo
DXCM
DexCom
3.04
Buy$91.9610.20% Upside
Illumina, Inc. stock logo
ILMN
Illumina
2.44
Hold$222.19-19.55% Downside
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
2.71
Moderate Buy$502.5317.83% Upside
Insulet Corporation stock logo
PODD
Insulet
2.46
Hold$193.4844.30% Upside

Current Analyst Ratings Breakdown

Latest ISRG, PODD, DXCM, and ILMN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/7/2026
Illumina, Inc. stock logo
ILMN
Illumina
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetUnderweight$160.00 ➝ $200.00
10/7/2026
DexCom, Inc. stock logo
DXCM
DexCom
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
10/7/2026
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
10/7/2026
Insulet Corporation stock logo
PODD
Insulet
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
10/6/2026
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$485.00
10/6/2026
Insulet Corporation stock logo
PODD
Insulet
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageUnderweight ➝ Equal Weight$150.00
10/6/2026
DexCom, Inc. stock logo
DXCM
DexCom
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageUnderweight ➝ Overweight$115.00
10/6/2026
DexCom, Inc. stock logo
DXCM
DexCom
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C) ➝ Hold (C+)
10/5/2026
Illumina, Inc. stock logo
ILMN
Illumina
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$230.00 ➝ $310.00
10/1/2026
Illumina, Inc. stock logo
ILMN
Illumina
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$226.00 ➝ $305.00
10/1/2026
DexCom, Inc. stock logo
DXCM
DexCom
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$90.00 ➝ $105.00
(Data available from 10/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
DexCom, Inc. stock logo
DXCM
DexCom
$4.66B6.75$2.74 per share30.45$7.04 per share11.85
Illumina, Inc. stock logo
ILMN
Illumina
$4.49B9.28$6.93 per share39.88$17.82 per share15.50
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$11.03B13.65$9.55 per share44.68$50.52 per share8.44
Insulet Corporation stock logo
PODD
Insulet
$3.05B3.05$6.31 per share21.25$21.54 per share6.22
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
DexCom, Inc. stock logo
DXCM
DexCom
$836.30M$2.5332.8827.091.4120.12%35.94%14.75%10/29/2026 (Estimated)
Illumina, Inc. stock logo
ILMN
Illumina
$850M$5.3651.5145.283.7918.36%29.84%12.17%10/29/2026 (Estimated)
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$2.86B$8.7348.8442.563.1328.45%16.91%14.83%10/20/2026 (Estimated)
Insulet Corporation stock logo
PODD
Insulet
$247.10M$5.3525.0217.391.0612.29%29.29%13.31%11/4/2026 (Confirmed)

Latest ISRG, PODD, DXCM, and ILMN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026Q3 2026
Insulet Corporation stock logo
PODD
Insulet
$1.59N/AN/AN/A$833.13 millionN/A
10/29/2026Q3 2026
DexCom, Inc. stock logo
DXCM
DexCom
$0.6730N/AN/AN/A$1.33 billionN/A
10/29/2026Q3 2026
Illumina, Inc. stock logo
ILMN
Illumina
$1.36N/AN/AN/A$1.15 billionN/A
10/20/2026Q3 2026
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$2.65N/AN/AN/A$2.91 billionN/A
8/5/2026Q2 2026
Insulet Corporation stock logo
PODD
Insulet
$1.47$1.66+$0.19$1.37$787.39 million$801.70 million
7/30/2026Q2 2026
DexCom, Inc. stock logo
DXCM
DexCom
$0.6110$0.70+$0.0890$0.64$1.29 billion$1.31 billion
7/30/2026Q2 2026
Illumina, Inc. stock logo
ILMN
Illumina
$1.23$1.31+$0.08$1.35$1.13 billion$1.16 billion
7/16/2026Q2 2026
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$2.48$2.80+$0.32$2.29$2.83 billion$2.89 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
Illumina, Inc. stock logo
ILMN
Illumina
N/AN/AN/AN/AN/A
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
N/AN/AN/AN/AN/A
Insulet Corporation stock logo
PODD
Insulet
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
DexCom, Inc. stock logo
DXCM
DexCom
0.47
1.73
1.43
Illumina, Inc. stock logo
ILMN
Illumina
0.53
1.80
1.40
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
N/A
4.96
3.91
Insulet Corporation stock logo
PODD
Insulet
0.65
2.48
1.83

Institutional Ownership

CompanyInstitutional Ownership
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
Illumina, Inc. stock logo
ILMN
Illumina
89.42%
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
83.64%
Insulet Corporation stock logo
PODD
Insulet
N/A

Insider Ownership

CompanyInsider Ownership
DexCom, Inc. stock logo
DXCM
DexCom
0.28%
Illumina, Inc. stock logo
ILMN
Illumina
2.90%
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
0.60%
Insulet Corporation stock logo
PODD
Insulet
0.36%
CompanyEmployeesShares OutstandingFree FloatOptionable
DexCom, Inc. stock logo
DXCM
DexCom
11,000377.36 million376.30 millionOptionable
Illumina, Inc. stock logo
ILMN
Illumina
8,650151.00 million146.62 millionOptionable
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
17,021353.28 million351.16 millionOptionable
Insulet Corporation stock logo
PODD
Insulet
5,40069.35 million69.10 millionOptionable

Recent News About These Companies

Barclays initiates coverage of Insulet with equal-weight rating
October 8 at 7:04 AM  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/barclays-initiates-coverage-of-insulet-with-equal-weight-rating/ar-AA2dLKk9
Insulet (NASDAQ:PODD) Stock Moved Up to Hold by Barclays
October 8 at 6:06 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31099322
Insulet (NASDAQ:PODD) Upgraded to Hold at Barclays
October 8 at 6:05 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-insulet-nasdaq-podd-upgraded-to-hold-at-barclays-2026-10-08/
Analysts Offer Insights on NA Companies: Insulet (PODD) and General Motors (GM)
October 1, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/PODD/pressreleases/4900484/analysts-offer-insights-on-na-companies-insulet-podd-and-general-motors-gm/
Insulet to Announce Third Quarter 2026 Financial Results on November 4, 2026
October 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/insulet-announce-third-quarter-2026-110000772.html
Insulet Corporation (NASDAQ:PODD) Stock Now Rated "Hold" by Wall Street Analysts
September 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31068448
Insulet Corporation (NASDAQ:PODD) Stock Has Consensus Target Price of $195.40
September 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-insulet-corporation-nasdaq-podd-stock-has-consensus-target-price-of-19540-2026-09-30/
Comparing Nano-X Imaging (NASDAQ:NNOX) and Insulet (NASDAQ:PODD)
September 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31068143
Insulet Sees Emerging Headwinds From New Market Entrants in 2027, 2028, Oppenheimer Says
September 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/insulet-sees-emerging-headwinds-market-153342394.html
Insulet Sees Emerging Headwinds From New Market Entrants in 2027, 2028, Oppenheimer Says
September 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/insulet-sees-emerging-headwinds-market-153342394.html
Insulet (PODD) Stock May Trade At A Discount To Fair Value
September 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/insulet-podd-stock-may-trade-051043414.html
Insulet (PODD) Reworked Its Debt, Is The Stock Still Cheap?
September 25, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/insulet-podd-reworked-debt-stock-111220704.html
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
September 25, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2995879/why-insulet-podd-is-a-top-growth-stock-for-the-long-term?cid=cs-stocknewsapi-ft-fundamental_analysis|zacks_education_growth_score-2995879
Insulet Targets Type 2 Retention as Omnipod 6 and Global Growth Gain Momentum
September 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/event-insulet-targets-type-2-retention-as-omnipod-6-and-global-growth-gain-momentum-2026-09-25/
Insulet Corporation (PODD) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
September 24, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4949558-insulet-corporation-podd-presents-at-bernstein-insights-healthcare-leaders-and-disruptors-3rd
How Is Insulet's Stock Performance Compared to Other Medical Devices Stocks?
September 24, 2026  |  barchart.comhttps://www.barchart.com/story/news/4771377/how-is-insulet-s-stock-performance-compared-to-other-medical-devices-stocks
Insulet stock heads into the open after a flat Nasdaq close
September 22, 2026  |  ad-hoc-news.deA
Nykredit A S Makes New Investment in Insulet Corporation $PODD
September 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-nykredit-a-s-makes-new-investment-in-insulet-corporation-podd-2026-09-22/
Insulet stock gains as Bank of America stake and guidance highlight upside potential
September 21, 2026  |  ad-hoc-news.deA
Insulet Amends Credit Facilities, Expands Revolving Commitments
September 21, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/insulet-amends-credit-facilities-expands-revolving-commitments?utm_source=marketbeat.com&utm_medium=referral
426,409 Shares in Insulet Corporation $PODD Bought by Bank of America Corp DE
September 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-426409-shares-in-insulet-corporation-podd-bought-by-bank-of-america-corp-de-2026-09-20/

New MarketBeat Followers Over Time

Media Sentiment Over Time

DexCom stock logo

DexCom NASDAQ:DXCM

$83.44 -0.97 (-1.14%)
As of 02:50 PM Eastern
This is a fair market value price provided by Massive. Learn more.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Illumina stock logo

Illumina NASDAQ:ILMN

$276.18 +11.61 (+4.39%)
As of 02:50 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Intuitive Surgical stock logo

Intuitive Surgical NASDAQ:ISRG

$426.50 +11.09 (+2.67%)
As of 02:50 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.

Insulet stock logo

Insulet NASDAQ:PODD

$134.08 -0.39 (-0.29%)
As of 02:50 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas